The Paraquat lawsuit: how MDL 3004 stands after the Philadelphia bellwether settlements

Paraquat is one of the most acutely toxic herbicides ever developed. The chemical, marketed in the United States primarily as Gramoxone since the 1960s, is so dangerous that the EPA classifies it as a Restricted Use Pesticide (RUP), the most stringent regulatory category, with applications limited to certified applicators. A single sip can be fatal. Decades of agricultural use have produced a body of scientific literature linking long-term Paraquat exposure to Parkinson's disease in farmers, agricultural workers, and others with sustained occupational contact. The mass tort litigation that emerged from this scientific record has grown into one of the larger active product liability proceedings in the U.S. federal court system.

As of December 2025, MDL 3004 (In re: Paraquat Products Liability Litigation), centralized in the U.S. District Court for the Southern District of Illinois before Chief Judge Nancy J. Rosenstengel, had 6,470 pending cases. Approximately 1,799 additional cases are pending in the Philadelphia Court of Common Pleas under Judge Joshua Roberts in a parallel state court litigation track. The defendants are Syngenta (the current manufacturer, a Swiss multinational that traces back to Imperial Chemical Industries which originally developed Paraquat in the 1950s) and Chevron USA (a former distributor in the United States from the 1960s through the 1980s).

The procedural posture in 2026 is mixed and changing. The first federal bellwether trial was scheduled for October 14, 2025, but Judge Rosenstengel vacated it to facilitate settlement discussions. The first Philadelphia state court bellwether trial was scheduled for January 26, 2026, but settled on January 27, the night before opening statements. A second Philadelphia bellwether is scheduled for April 13, 2026, with prominent plaintiffs' trial counsel R. Brent Wisner serving as lead trial attorney. The MDL stay on case-specific deadlines has been extended multiple times, most recently through March 6, 2026, indicating that settlement negotiations are continuing but haven't produced a global resolution.

This is the science connecting Paraquat to Parkinson's disease, the legal framework operating across federal MDL and state court litigation, the bellwether developments and what they mean for settlement negotiations, and what filing-eligible claims look like in 2026.

The science: Paraquat and Parkinson's disease

Paraquat dichloride is a contact herbicide that kills plants by interfering with their cellular respiration. The chemical was developed in the 1950s by Imperial Chemical Industries (which became Syngenta through a series of corporate mergers and spinoffs) and first commercialized in 1962. Paraquat became one of the world's most widely used herbicides for agricultural applications including weed control in fields, drying crops before harvest, and clearing brush.

The toxicity profile is severe. Acute exposure (a single substantial dose) is often fatal because Paraquat causes irreversible lung damage that progresses over days to weeks even after exposure has ceased. There is no antidote. The EPA classifies Paraquat as a Restricted Use Pesticide with applications limited to certified applicators who have completed specific training; products sold for residential use are prohibited. The chemical is banned in the European Union, China, Brazil, and many other jurisdictions, but remains in agricultural use in the United States, Canada, and several other countries.

The Parkinson's disease connection emerged through decades of scientific research:

Animal studies dating to the 1980s established that Paraquat causes selective destruction of dopaminergic neurons in the substantia nigra, the brain region whose degeneration is the hallmark of Parkinson's disease. The cellular mechanism involves oxidative stress and mitochondrial dysfunction, which match the cellular signatures of Parkinson's disease in human patients.

Epidemiological studies of agricultural worker populations have repeatedly found increased Parkinson's disease rates among workers with documented Paraquat exposure. A 2011 study by Tanner et al. in Environmental Health Perspectives found that agricultural workers with high Paraquat exposure had approximately 2.5 times the Parkinson's disease risk of unexposed workers. Multiple subsequent studies have confirmed this association.

The International Agency for Research on Cancer (IARC) and various other scientific bodies have evaluated the evidence and concluded that Paraquat exposure is causally associated with increased Parkinson's disease risk in agricultural worker populations.

The biological plausibility argument has been particularly strong in this litigation compared to other mass torts. The cellular mechanism is well-characterized, the dose-response relationships are documented, and the epidemiological associations are consistent across multiple studies. The Daubert exclusion concerns that defeated the Tylenol autism MDL haven't been the central issue in Paraquat litigation, though specific expert challenges have occurred.

The legal framework

The Judicial Panel on Multidistrict Litigation established MDL 3004 in June 2021, consolidating federal Paraquat cases in the Southern District of Illinois. The MDL operates under the standard multidistrict litigation framework codified at 28 U.S.C. §1407, which we cover generally in our overview of how mass tort settlements work.

The case theories center on:

Product liability claims alleging that Syngenta and Chevron failed to warn agricultural workers and consumers about the Parkinson's disease risks despite extensive internal corporate knowledge of the toxicological evidence.

Negligent design claims alleging that the products should have been formulated differently or sold with different precautions to reduce exposure risk.

Strict liability claims under state laws that don't require proof of specific negligence.

Failure to provide adequate Material Safety Data Sheets (MSDS) and other required safety documentation to applicators.

Concealment claims alleging that internal corporate documents show the manufacturers were aware of Parkinson's disease risks but didn't disclose them.

State court parallel litigation has emerged as a substantial track. The Philadelphia Court of Common Pleas under Judge Joshua Roberts has approximately 1,799 cases, the largest concentration outside the federal MDL. Pennsylvania has been particularly significant because of its consent-by-registration jurisdictional doctrine: corporations registered to do business in Pennsylvania can be sued there regardless of where the underlying claims arose. In October 2025, the U.S. Supreme Court denied review of Syngenta's challenge to Pennsylvania's consent-by-registration framework, leaving the broad jurisdictional reach intact.

Bellwether developments

The bellwether trial track has been substantially disrupted by procedural developments and settlement activity.

Initial federal bellwether selection. Judge Rosenstengel selected an initial group of bellwether cases for trial preparation. Four of those cases were dismissed in 2024 after the court excluded the testimony of one of the plaintiffs' general causation experts under Daubert standards. The plaintiffs subsequently developed additional expert testimony to support the well-established scientific link between Paraquat and Parkinson's disease.

New bellwether selection. Following the initial dismissals, plaintiffs and defendants worked through additional bellwether case selection. In January 2025, Judge Rosenstengel set the first new federal bellwether for October 14, 2025.

October 2025 bellwether vacated. Judge Rosenstengel vacated the October 14, 2025 trial date to facilitate settlement discussions while maintaining discovery deadlines through January 5, 2026. The vacatur reflected judicial recognition that settlement was the more likely outcome than trial; settlement negotiations had been ongoing since April 2025 when a settlement in principle was announced.

January 2026 Philadelphia bellwether settled on the eve of trial. The first Philadelphia state court bellwether trial was scheduled for January 26, 2026. The case settled on January 27, the night before opening statements were scheduled to begin. The settlement terms were not publicly disclosed. Motley Rice attorney Mike Daly served as local trial counsel on the case. The pattern of settling cases on the eve of trial is a recurring feature of Paraquat litigation; defendants have shown clear preference for confidential settlements over jury verdicts that would create precedent for valuation of other cases.

April 2026 Philadelphia bellwether scheduled. The second Philadelphia bellwether is scheduled for April 13, 2026, with Wisner Baum managing partner R. Brent Wisner serving as trial counsel. Wisner has substantial experience with toxic tort litigation including Roundup cases where he won the first jury verdict against Monsanto. Whether this trial actually goes to verdict or settles like the prior bellwether will substantially affect settlement leverage going forward.

MDL stay extensions. The MDL judge has extended the stay on case-specific deadlines multiple times, most recently through March 6, 2026, citing ongoing settlement process. The pattern of stay extensions indicates that settlement framework discussions are continuing but full agreement hasn't been reached.

The settlement landscape

A settlement in principle was announced in April 2025. The framework reportedly includes:

A tiered compensation structure based on severity of Parkinson's disease diagnosis, duration of Paraquat exposure, age at diagnosis, and other factors.

A total settlement value reported in various sources at $2 billion to $5 billion, though specific figures have not been officially confirmed.

A claim administration process administered by an independent claims administrator.

Tiered eligibility requirements requiring documented Paraquat exposure and confirmed Parkinson's disease diagnosis.

Specific terms for plaintiffs' attorneys and primary counsel arrangements.

Final agreement hasn't been reached because some plaintiff firms have raised objections to specific terms or resist accepting the framework. The settlement in principle covers the majority of pending cases, but holdout firms and cases with specific characteristics may pursue separate negotiations or trials.

Eligibility for filing

The Paraquat litigation framework remains open for new filers who meet specific criteria.

You may have a viable claim if:

You have documented exposure to Paraquat or other glyphosate-based herbicides over a substantial period. The exposure context typically involves agricultural work (farming, agricultural application), groundskeeping, landscape work, or other sustained occupational use. Brief or one-time exposure rarely supports a viable case.

You have a confirmed diagnosis of Parkinson's disease. The medical documentation needs to include neurologist evaluation, imaging studies (if applicable), and clear diagnostic criteria. Pseudo-Parkinsonian conditions (drug-induced parkinsonism, vascular parkinsonism) generally don't fit the litigation framework because the causation theory is specific to true Parkinson's disease.

Your exposure occurred while Paraquat use was authorized in the United States. Paraquat has been continuously authorized for restricted use since 1962, so this is rarely an issue except for very recent or very old exposure histories.

Your filing falls within the relevant statute of limitations. Statutes of limitation for personal injury claims typically run 2 to 4 years from the date the plaintiff knew or should have known of the connection between Paraquat exposure and the Parkinson's disease diagnosis. The discovery rule in many states extends the deadline when the connection wasn't immediately apparent.

The strongest cases involve:

Long-term documented Paraquat use (typically multiple years of regular exposure as part of agricultural or related occupational work).

Clear Parkinson's disease diagnosis with appropriate medical documentation.

Documentation of the exposure (employment records, agricultural records, witness statements, etc.).

Diagnosis within a reasonable temporal window after the exposure history; very recent diagnosis with long-ago exposure is more challenging to connect than cases with closer temporal proximity.

Wrongful death claims. If a family member died from Parkinson's disease or related complications linked to Paraquat exposure, the estate or surviving family may have viable wrongful death claims subject to state-specific procedural requirements.

What's not eligible

Several categories don't fit the current Paraquat litigation framework:

Conditions other than Parkinson's disease. The litigation is structured around Parkinson's disease specifically. Other neurological conditions (Alzheimer's, dementia, multiple sclerosis, ALS) generally don't fit the framework even if there's some association with chemical exposure.

Drug-induced parkinsonism. Parkinsonism caused by medication side effects (particularly antipsychotic medications) is medically distinct from idiopathic Parkinson's disease and doesn't fit the litigation theory.

Cases with insufficient exposure history. Brief, occasional, or one-time Paraquat exposure rarely supports a viable case because the causation theory requires sustained exposure to produce the dopaminergic neuron damage that leads to Parkinson's disease.

Cases beyond the statute of limitations. Strict state limits apply, and Parkinson's disease cases with long delays between exposure and diagnosis sometimes fall outside the filing window.

Other herbicide exposure. Many lawsuits involving agricultural chemical exposure target Roundup/glyphosate for cancer claims rather than Paraquat for Parkinson's claims. The two litigations involve different chemicals, different injuries, and different legal frameworks despite some surface similarities.

What to do if you may have a claim

Consult with a mass tort attorney experienced specifically with Paraquat litigation. Most attorneys handling these cases offer free initial consultations and work on contingency. The attorney can evaluate whether your specific facts fit the litigation framework, advise on the strategic decision between joining settlement framework versus pursuing individual claim, and outline the procedural path.

Document the exposure history. Employment records showing agricultural work or other Paraquat-exposed occupations. Witness statements from coworkers, family members, or others who can corroborate the exposure history. Photographs from the work environment if available. Agricultural application records (in some cases, these were maintained by the employer and may be obtainable). Specific identification of Paraquat or Gramoxone products if possible (brand identification helps the case).

Gather medical records. Neurologist evaluations documenting the Parkinson's disease diagnosis. Imaging studies (DAT scans, MRI) if performed. Treatment records and progression notes. Records of medications prescribed and their effects. The longer and clearer the documented Parkinson's disease history, the stronger the case.

Don't delay. Statutes of limitation are strict, and the discovery rule in some states still has limits. Cases that aren't filed within the deadline are generally barred regardless of merit. With the settlement framework being negotiated and bellwether trials ongoing, the window for participating in the structured resolution is narrower than it was earlier in the litigation.

Be realistic about timing. Even if the case is strong, resolution may take several years. The settlement framework discussions are continuing, individual case evaluation takes time, and even cases pursued individually through trial typically take 2 to 4 years from filing to resolution. Plaintiffs need to be prepared for an extended process.

Strategic choices. Joining the settlement framework (when finalized) provides defined compensation in defined timeframes but typically lower per-case recovery than potential trial verdicts. Pursuing individual litigation provides potential for higher recovery but with risk and substantial time investment. The strategic choice depends on case strength, individual financial circumstances, and risk tolerance.

The Paraquat litigation represents one of the more procedurally complex active mass torts. The settlement framework is being negotiated, bellwether trials are producing eve-of-trial settlements that don't establish public valuation benchmarks, and the federal MDL stays in extended discovery posture pending settlement progress. For agricultural workers and others with documented Paraquat exposure and Parkinson's disease diagnoses, the legal framework provides meaningful paths to recovery, but the procedural realities require experienced counsel and patience. The science underlying the claims is among the strongest in any active mass tort, which has driven the substantial settlement activity even without public trial verdicts establishing valuation benchmarks.